Neuro-Oncological Clinical Outcomes Assessment

Neuro-oncological clinical outcomes assessment centres on quantifying treatment efficacy and patient well-being in brain tumour care. This discipline integrates conventional endpoints such as overall and progression-free survival with patient-centred measures including symptom burden, cognitive function and quality of life. Advances in neuroimaging biomarkers and statistical modelling have refined approaches to distinguish true progression from treatment effects such as pseudoprogression. Concurrently, emerging machine-learning techniques offer predictive risk stratification and personalised prognostication. Standardised clinical outcome assessments are increasingly embedded in trial design, guiding regulatory approvals and informing multidisciplinary care pathways. Harmonisation of outcome measures, coupled with rigorous data acquisition and analysis, underpins evidence synthesis across centres and supports real-world implementation. The field continues to evolve through collaborative initiatives that align methodological rigour with the priorities of patients and clinicians, fostering improvements in survival, function and life quality for those affected by brain tumours.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neuro-Oncological Clinical Outcomes Assessment publication trend

The graph below shows the total number of articles in neuro-oncological clinical outcomes assessment across all publications each year (not limited to Nature Index journals).

Technical terms

Clinical outcome assessment: evaluation of the effects of disease and treatment on patient health, function and quality of life.

Progression-free survival: length of time during which a patient’s disease does not worsen.

Overall survival: duration from diagnosis or treatment start until death from any cause.

Pseudoprogression: transient radiological changes mimicking disease progression but reflecting treatment-related effects.

Cox proportional hazards regression: statistical model estimating the effect of variables on the hazard of an event over time.

Gated recurrent unit (GRU): type of recurrent neural network cell that models sequential data by retaining information over time.

Fuzzy logic: computational approach allowing reasoning with uncertain or imprecise information by assigning degrees of membership to variables.

References

1. Application of deep learning-based fuzzy systems to analyze the overall risk of mortality in glioblastoma multiforme. Machine Learning: Science and Technology (2024).
2. Influence of MRI Follow-Up on Treatment Decisions during Standard Concomitant and Adjuvant Chemotherapy in Patients with Glioblastoma: Is Less More?. Cancers (2023).
3. Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study. Journal of Neuro-Oncology (2024).